Phylloceuticals2
Phylloceuticals2
  • Home
  • Our Team
    • OUR TEAM
    • Bill Brydges, M.S.
    • Dan Hanson, M.S.
    • R. Barry Holtz, Ph.D.
    • Susan Stipa
    • Mark Brown, Ph.D.
    • Lynn Dickey, Ph.D.
    • Curt Cornwell
    • Kathleen Brunner
  • Technology
  • Markets
  • News
    • News
    • Phylloside Chats
    • Press Release
  • Contact Us
  • More
    • Home
    • Our Team
      • OUR TEAM
      • Bill Brydges, M.S.
      • Dan Hanson, M.S.
      • R. Barry Holtz, Ph.D.
      • Susan Stipa
      • Mark Brown, Ph.D.
      • Lynn Dickey, Ph.D.
      • Curt Cornwell
      • Kathleen Brunner
    • Technology
    • Markets
    • News
      • News
      • Phylloside Chats
      • Press Release
    • Contact Us
  • Home
  • Our Team
    • OUR TEAM
    • Bill Brydges, M.S.
    • Dan Hanson, M.S.
    • R. Barry Holtz, Ph.D.
    • Susan Stipa
    • Mark Brown, Ph.D.
    • Lynn Dickey, Ph.D.
    • Curt Cornwell
    • Kathleen Brunner
  • Technology
  • Markets
  • News
    • News
    • Phylloside Chats
    • Press Release
  • Contact Us

Welcome to Phylloceuticals

A Global Company Dedicated to Making Affordable Medicine


The lack of global supply of necessary medicines can be addressed by increasing the geographic diversity of production around the world. Investing in advanced manufacturing, strengthening international regulatory cooperation, and creating additional transparency in the supply chain is imperative. Biopharma systems such as plant-made pharmaceuticals can lower the capital required for entry into the biologics market. Phylloceutical Ventures was established to address these vulnerabilities and enhance the world’s ability to supply biologics to all populations.


Phylloceuticals uses a plant-made technology which offers lower overall investment and a much quicker response time for drug development. 


Founded with a mission to provide affordable pharmaceuticals to the world, Phylloceuticals is a company with a revolutionary business model.

 

Using the power of plant-made pharma technology, Phylloceuticals was formed to address breakdowns in national and international pharmaceutical supply chains that were made evident during the Covid-19 pandemic. It is now a global public health priority to strengthen these national supply chains. An uninterrupted supply of essential medicines that are safe and effective is a priority for the U.S. and for every nation. 

About Us

Phylloceuticals partners are a rare group of individuals and companies who came together in 2020 with a grand idea - use their decades of experience to help get medicine to underserved areas of the world and underserved biologics markets. This team provides deep sector expertise in all facets of plants, biologics development, investment know-how, and project & product launch. 


The Phylloceuticals Executive Team has worked together on multiple, and award winning projects, over their decades of contribution to biologics industry. This deeply shared history delivers intuitive and experienced solutions for Phylloceuticals clients and led to the formation of the Phytopharma as a Sustainable Technology (PhAAST™) Platform.

Our Team

  The Phylloceuticals team has been working on projects together for decades and is now on a mission to produce affordable medicine on a scale that will alleviate global production capacity limitations. 


From early stage funding, drug discovery and development, regulatory strategy, to engineering and construction, the ‘dream team’ at Phylloceuticals is sought out globally for their unique blend of expertise.  [READ MORE]

WHO WE ARE




Bill Brydges, M.S.




Dan Hanson, M.S.




R. Barry Holtz, Ph.D.




Susan Stipa




Mark Brown, Ph.D.




Lynn Dickey, Ph.D.




Curt Cornwell




Kathleen Brunner

Subscribe

Sign up to receive updates, news, and more.

  • Home
  • Terms and Conditions